Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.1Synthetic dopamine precursor
What ifWhat if a chemically synthesized dopamine precursor supplies the active ingredient?
Claim language“Allium senescens extract”
An oral tablet releases levodopa, which crosses the blood-brain barrier through a large neutral amino acid transporter. Aromatic L-amino acid decarboxylase converts levodopa to dopamine in the brain, improving motor symptoms associated with dopamine depletion.
1.1Cerebrospinal fluid antisense delivery
What ifWhat if a synthetic antisense oligonucleotide supplies the active ingredient?
Claim language“Allium senescens extract”
An intrathecal injection delivers an antisense oligonucleotide that binds a complementary sequence in superoxide dismutase 1 messenger RNA. Ribonuclease H1 cleaves the RNA strand of the resulting duplex, reducing production of the protein in patients with the corresponding genetic form of motor neuron disease.
1.1Antibody binding to amyloid
What ifWhat if a recombinant antibody supplies the active ingredient?
Claim language“Allium senescens extract”
Cultured mammalian cells produce a monoclonal antibody that binds aggregated amyloid beta, and an intravenous infusion delivers the purified antibody. Antibody binding promotes clearance of amyloid deposits through immune cells in the brain.
1.1Glutamate receptor channel blockade
What ifWhat if a synthetic glutamate receptor blocker supplies the active ingredient?
Claim language“Allium senescens extract”
An oral tablet delivers memantine, which enters open N-methyl-D-aspartate receptor channels and limits prolonged ion flow. This action reduces excessive receptor activation and provides symptomatic treatment for moderate to severe dementia associated with amyloid and tau pathology.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
No entries.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
1.1Allium senescens extract as an active ingredient.
More specifically, the soap was made by the applicant in a known method for making soap, however, added in the soap as active ingredients for reducing hair loss and/or for hair growth are extracts of Allium fistulosum, in particular, the plants called “Pa” or “Dae-Pa” (in Korean language) which are a relatively big and thick sort of bunching onions or great green onions available in Korean or Asian groceries (which may be similar to those called “Cong” or “Da cong” in Chinese
A · US 2007/0065395 A1 · ¶ 17
The term extract of Allium species or aqueous-alcoholic extract of Allium species refers particularly to aqueous-alcoholic extracts and native extracts obtained from all species of the genus Allium (family Liliaceae) and especially Allium cepa.
B · US 2013/0323334 A1 · ¶ 19
An empty cell means only that no passage was reproduced there.
Statements in these documents
The present invention relates to topical compositions and hair and skin care products containing plant extracts or components usable for stimulating hair growth and reducing hair loss.
A · US 2007/0065395 A1 · ¶ 1
However, notwithstanding the large number of plant-derived materials reported to possess therapeutic properties, there still exists a need for novel plant extracts and therapeutic use thereof as such therapies may be safer and more cost effective than traditional medical treatments.
A · US 2007/0065395 A1 · ¶ 8
The invention concerns a new use of compositions containing as active ingredient an extract of Allium species, an extract of Citrus species, an extract of Paullinia species and an extract of Theobroma species, preventing CRIA (Chemotherapy and Radiotherapy Induced Alopecia), reducing CRIA impact and improving the appearance of hair re-growth after CRIA , and methods thereof.
B · US 2013/0323334 A1 · ¶ 1
At the cellular level, CRIA (Chemotherapy and Radiotherapy Induced Alopecia) originates from the premature on-set of the catagen phase of the hair due to the destruction (apoptosis) by a chemotherapy agent of the cells in the hair follicles, especially the cells linking the hair to the dermal papilla.
B · US 2013/0323334 A1 · ¶ 5
Cite aspatent.fyi, US 2026/0355272 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355272/, SHA-256 3724c9a7989f34acaf65e7a3602004ce54733e2870051ac6291202b7d08c6caf